Noel Wallace: Yeah. Good morning, Rob. Thank you. Let me take the e-commerce question first. A good year for e-commerce, as I mentioned, it’s up to 14% of our sales. We continue to see strong growth throughout the year, and importantly, in the most important markets around the world, we continue to see strong share growth. So, overall, we feel a lot of the work that we put into our digital transformation has paid out quite nicely in the consumption that we are seeing across the board, whether that’s our skin business, whether that’s our U.S. Oral Care business or our Hill’s business, we are performing quite well. And we are sharing those capabilities very nicely across the enterprise, and as I have talked to you before in the past, obviously, Hill’s was at the forefront of that and a lot of the skill sets that we built in our Hill’s organization have certainly translated now across the enterprise and we are using those benefits to grow our e-commerce business, both on a share basis and a topline basis.
The inventory drawdown was on PCA and Elta in the U.S. in the online channel, which is their number one retail channel. As you know, they sell through the profession and they sell online through the big online retailers. The big online retailers took significant inventory out of the system in the fourth quarter. These are very high priced items, as you are well aware, and they felt, I guess, managing their working capital that they were going to take those down in the fourth quarter. The good news, as I mentioned earlier, we didn’t see a significant impact on our consumption. Our shares were actually up and the more important news is that we started to see that inventory rebuild itself slowly, I would say, in the first quarter of this year, particularly January.
Now that’s not to say that at the end of the quarter, we may see more draw downs. But in any case, the good news is we start to see some improvements there. But it was on the PCA and Elta business in the U.S. And likewise, on the Filorga business in China with the significant lockdowns that we saw across China in the fourth quarter and coming out of the third quarter, we saw significant inventory reductions in the online business there as well. Relative to private label, let me characterize, I guess, first Oral Care. So Oral Care private label in the U.S. is about 0.9 share and that share is roughly flat on the quarter — in the fourth quarter and flat on the year. Oral Care private label shares in Europe are around 3.5%, and likewise, that share is flat.
We are seeing a little bit of growth in private label businesses, particularly in Europe on some of the Home Care businesses. Obviously, cleaners dish, and to a certain extent, fabric softener, as we have seen about 1 point of growth in the private label business there, but consistent with where we expected. So nothing unusual, and importantly, we don’t see, obviously, given the benign levels of shares we have seen in Oral Care, we haven’t seen a significant turnaround there. On the Hill’s trade-down, we have not seen trade-down thus far. If you go back to 2007, 2008, which we spent a lot of time looking at the premiumization of the category during that period. We did not see consumers pulling back on scientific — scientifically proven Pet Nutrition.
And we feel that given the strength of our innovation, and obviously, the strength of the investment that we are putting in the market, that we will be able to continue to manage that quite well.
